ClinicalTrials.gg
CompletedNCT03519828Updated Jul 31, 2019

Oxidation-reduction Homeostasis in Cognitive Impairment Patients After Stroke

An observational study in Oxidative-reduction Homeostasis and Post-stroke Cognitive Impairment, sponsored by Hui-Sheng Chen. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Hui-Sheng Chen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Enrollment
93rd of 119
100 · median 300
Started
2018
with 8 others
Observational
119 of 310
64 open now
Registered
57th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 93rd largest by enrollment of the 119 observational ones that give a count, is one of 9 that started in 2018, is one of 119 observational ones, and was the 57th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

Cognitive impairment after ischemic stroke can affect not only the social adaptation ability, but also affect the comprehensive rehabilitation of patients. The damage of cognitive impairment after ischemic stroke is not lower than the body function defect after stroke. Many studies have shown that oxidative stress is one of the pathophysiological mechanisms of ischemic cerebrovascular disease. Many studies have reported that the oxidative-reduction of cells plays an important role in the life activities of organisms, affecting the health, aging and death of the organism. In the recent years, some scholars have suggested that post-stroke cognitive impairment may be related to oxidative-reduction homeostasis of the body, but the relevant evidence is lacking and needs to be further explored. Therefore, the purpose of this study is to explore the effect of oxidation-reduction homeostasis on cognitive impairment in patients with ischemic stroke, and provide a theoretical basis for the prevention and treatment of cognitive impairment after ischemic stroke.

03

Conditions studied

  • Oxidative-reduction Homeostasis
  • Post-stroke Cognitive Impairment
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acute ischemic stroke patients in hospital from March, 2018 to September, 2018.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40-80 years old;
  • Ischemic stroke for the first time or previous stroke but with no serious sequelae (mRS is 0 -2 points);
  • Time from onset to treatment ≤48 hours;
  • Conscious awareness, and with no obvious aphasia and visual impairment;
  • Signed by patient self or legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage or suspected subarachnoid hemorrhage;
  • ;
  • Patients with severe mental disorders or language disorders;
  • Patients can not cooperate with evaluators, such as mental illness or dementia;
  • Pregnant women or suckers;
  • Researchers consider patients inappropriate to participate in the registry.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with post-stroke cognitive impairment

    Other: No intervention has been conducted

  • Patients without post-stroke cognitive impairment

    Other: No intervention has been conducted

Interventions

  • OtherNo intervention has been conducted

    It is an observational study, and no intervention has been conducted

06

What researchers measure

Primary outcomes

  1. Oxidative-reduction homeostasis in acute ischemic stroke patients

    Reduced glutathione (GSH)/ Oxidized glutathione (GSSG), Superoxide dismutase (SOD), Catalase (CAT), Glutathione Peroxidase (GSH-PX) of acute ischemic stroke patients will be tested.

    Time frame: 1 day

  2. Cognitive function in acute ischemic stroke patients

    Mini Mental Status Examination (MMSE) and Montreal cognitive assessment scale (MoCA) in acute ischemic stroke patients will be evaluated.

    Time frame: 1 day

07

Study locations

1 site
  • General Hospital of ShenYang Military Region
    Shenyang, Liaoning 10016, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Dec 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2018
First posted
May 9, 2018
StartActual
Mar 1, 2018
Primary completionActual
Dec 30, 2018
CompletionActual
Jan 1, 2019
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03519828
Lead sponsor
Hui-Sheng Chen
Responsible party
Hui-Sheng Chen (Professor, General Hospital of Shenyang Military Region) — Sponsor-investigator
First posted
May 9, 2018
Start date
Mar 1, 2018
Primary completion
Dec 30, 2018
Completion
Jan 1, 2019
Last update
Jul 31, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion